Using RWE to Accelerate Market Access in Rare Diseases

    14 – 15 March 2022, online training


    This unique training focuses on leveraging patient-centric Real-World Evidence (RWE) to accelerate the patient and market access of innovative and potentially transformative Orphan Medicinal Products (OMPs). Delegates will address the challenge of early market access based on fewer and less mature data, with the creation of an Early Value Proposition and a Patient-Centric Evidence Generation Plan that comprehensively support value demonstration, product positioning, and that meets stakeholders’ requirements.

    Who should attend?

    C-level executives, Senior business development strategists, Portfolio executives, Pricing and market access executives, Medical affairs executives, Marketing and commercial executives, Patient advocates, Epidemiologists, Outcomes researchers and health economists, Big data and RWE researchers, Clinical and regulatory executives interested in incorporating value and access early in development

    Key Topics

    • Opportunities and Challenges in Orphan Medicinal Products (OMPs)
    • Rare Patient Empowerment & Involvement
    • Real-World Evidence (RWE) Throughout the Value Chain
    • Real-World Case Examples
    • Early Value Proposition and Evidence Generation Planning
    • Next-Generation OMP Market Access Strategies

    Learning Objectives

    • Why market access opportunities and challenges for OMPs are different from other drugs?
    • How to collaborate with patients & caregivers in rare conditions to generate patient-meaningful outcomes?
    • Leveraging applications of RWE for pricing and access success and throughout the lifecycle
    • To mitigate payer uncertainty by addressing the challenge of early market access with accelerated approvals and fewer clinical data
    • How to develop a next-generation market access strategy with a life-cycle full spectrum evidence generation plan that maximizes product value from launch to loss of exclusivity?
    • To differentiate and succeed in the increasingly competitive rare disease space with a “fast to patient” approach


    • Training materials will be provided in digital form
    • All delegates will receive digital and LinkedIn certificates


    ORPHA Strategy Consulting, CEO
    David Schwicker has biopharmaceutical consulting expertise spanning more than 25 years. Founder of ORPHA Strategy Consulting, and former Vice President with PAREXEL International in the United States. David is a sought-after expert for accelerating marketing authorization, time to launch, early patient and market access of ATMPs.
    Online Participation
    1 450 Price incl. VAT: 1 450

    Price per delegate including:

    Online participation

    Online workbook & materials


    PC, microphone, camera, stable internet connection and the Zoom application.

    Yes, we will make every effort to ensure best possible interaction. You will see the slides, interact with the trainer and fellow participants. Questions and group exercises will be facilitated through the online meeting platform.

    Yes, you can transfer the registration to a colleague at any time.

    Yes, you may transfer your registration to a different event up to one month before the scheduled dates, provided the training fee has been paid in full.

    Lydia Makori
    +421 222 200 543

    Training Details